Qualcomm and Novartis are working together to develop a next-gen connected version of the pharma's Breezhaler device that's used across its entire chronic obstructive pulmonary disease drug portfolio.
The deluge of uses for Apple's ResearchKit and HealthKit development tools seems to be starting in earnest. The latest entrants are a couple of apps aimed at chronic obstructive pulmonary disease (COPD) patients. One, from the non-profit COPD Foundation, hopes to enroll more than 75,000 COPD patients in a lung health research study, while the other is intended to offer the means for patients to better monitor and manage COPD.
Novartis won FDA approval for a combination COPD treatment it hopes can steal market share from entrenched rivals GlaxoSmithKline and Boehringer Ingelheim, planning to launch the inhaler next year.
Verona Pharma has come through one of the last major barriers between it and the start of a Phase IIb trial of its chronic obstructive pulmonary disease (COPD) drug. The news means that, after years of largely unsuccessful R&D into phosphodiesterase inhibitors, another company is nearly ready to test a product from the class in a late-phase trial.
In the latest move by a biopharma into med tech, Teva Pharmaceutical will acquire respiratory disease compliance startup Gecko Health Innovations for an undisclosed sum. This gives Teva its own in-house medication compliance tracking capabilities--and takes one of a handful of high-profile startups in this area off the market.
Boehringer Ingelheim has finalized the crowdsourced chronic obstructive pulmonary disease (COPD) R&D team it has spent the past 9 months putting together with BioMed X. The partners have tapped the University of Stuttgart's Renata Jurkowska to lead the initiative, which is an attempt by Boehringer to draw on expertise outside of its walls to better understand the epigenetics of COPD.
The only inhaler that administers a slow-moving mist to help respiratory patients inhale the medication is now FDA-approved for the long-term maintenance treatment of asthma, in addition to its previous indication to treat COPD.
Inhalers can be tricky devices to manufacture and for the second time in two weeks a drugmaker is having to recall inhalers because the devices may not deliver any drugs. Following last week's recall by AstraZeneca of asthma inhalers in Denmark, Boehringer Ingelheim is recalling in the U.S. tens of thousands of inhalers used to treat chronic obstructive pulmonary disease.
Melbourne, Australia-based Adherium has pulled off a major pharma partnership just ahead of a proposed listing on the Australian Stock Exchange. It expects to list on Aug. 26, raising up to $35 million and at least $20 million. A new deal that the smart inhaler player just disclosed with AstraZeneca can only enhance its public market prospects.
Philips touted a study in the Journal of Clinical Sleep Medicine concluding that the company's portable home ventilator greatly reduced hospital readmissions among COPD patients.